Safety and Biovigilance in Organ Donation (SAFEBOD): Protocol for a Population-Based Cohort Study.

biovigilance cohort study disease transmission infectious neoplasms organ organ donor safety surgery transplant transplant recipients

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
26 10 2020
Historique:
received: 16 02 2020
accepted: 22 09 2020
revised: 21 09 2020
entrez: 26 10 2020
pubmed: 27 10 2020
medline: 27 10 2020
Statut: epublish

Résumé

Tension lies between the need to increase access to organ transplantation and the equally urgent need to prevent inadvertent transmission of infectious diseases or cancer from organ donors. Biovigilance, or the evaluation of potential donors, is often time-pressured and may be based on incomplete information. The Safety and Biovigilance in Organ Donation (SAFEBOD) study aims to improve estimates of infection and cancer transmission risk and explore how real-time data access could support decision-making. We will link existing donor referral, actual donor, recipient, and health-outcome data sets from 2000-2015 in New South Wales. Organ donor data sets will include the Organ Donor Characterizing Risk-Profile of Donors Study, the National Organ Matching System, the Australian and New Zealand Organ Donor Register, and the Australian and New Zealand Living Donor Kidney Register. Recipient data sets will include the Australian and New Zealand Dialysis and Transplant Register, the Australian and New Zealand Cardiothoracic Register, the Australian and New Zealand Islet and Pancreas Register, and the Australian and New Zealand Liver Transplant Register. New South Wales health outcome data sets will include HIV and AIDS Notifications and Surveillance Data, the Notifiable Conditions Information Management System, Admitted Patient Data Collection, Emergency Department Data Collection, the Central Cancer Registry, and the Cause of Death Data Collection. We will link organ donors to transplant recipients and health outcomes data sets using probabilistic data-matching based on personal identifiers. Transmission and nontransmission events will be determined by comparing previous cases in donors and posttransplant cases in recipients. We will compare the perceived-risk at referral with the verified risk from linked health outcome data sets and the odds of cancer or contracting an infectious disease in organ recipients from donors based on their transmission-risk profile and estimate recipient survival by donor transmission risk group. Data were requested from each of the listed registries in September 2018, and data collection is ongoing. Linked data from all listed data sets are expected to be complete in September 2020. The SAFEBOD study will overcome current limitations in organ donation by accessing comprehensive information on referred organ donors and recipients in existing data sets. The study will provide robust estimates of disease transmission and nontransmission events based on recent data. It will also describe the agreement between perceived risk estimated at the time of referral and verified risk when all health outcome data are accessible. The improved understanding of transmission and nontransmission events will inform clinical decisions and highlight where current policies can be revised to broaden the acceptance of deceased donors. DERR1-10.2196/18282.

Sections du résumé

BACKGROUND
Tension lies between the need to increase access to organ transplantation and the equally urgent need to prevent inadvertent transmission of infectious diseases or cancer from organ donors. Biovigilance, or the evaluation of potential donors, is often time-pressured and may be based on incomplete information.
OBJECTIVE
The Safety and Biovigilance in Organ Donation (SAFEBOD) study aims to improve estimates of infection and cancer transmission risk and explore how real-time data access could support decision-making.
METHODS
We will link existing donor referral, actual donor, recipient, and health-outcome data sets from 2000-2015 in New South Wales. Organ donor data sets will include the Organ Donor Characterizing Risk-Profile of Donors Study, the National Organ Matching System, the Australian and New Zealand Organ Donor Register, and the Australian and New Zealand Living Donor Kidney Register. Recipient data sets will include the Australian and New Zealand Dialysis and Transplant Register, the Australian and New Zealand Cardiothoracic Register, the Australian and New Zealand Islet and Pancreas Register, and the Australian and New Zealand Liver Transplant Register. New South Wales health outcome data sets will include HIV and AIDS Notifications and Surveillance Data, the Notifiable Conditions Information Management System, Admitted Patient Data Collection, Emergency Department Data Collection, the Central Cancer Registry, and the Cause of Death Data Collection. We will link organ donors to transplant recipients and health outcomes data sets using probabilistic data-matching based on personal identifiers. Transmission and nontransmission events will be determined by comparing previous cases in donors and posttransplant cases in recipients. We will compare the perceived-risk at referral with the verified risk from linked health outcome data sets and the odds of cancer or contracting an infectious disease in organ recipients from donors based on their transmission-risk profile and estimate recipient survival by donor transmission risk group.
RESULTS
Data were requested from each of the listed registries in September 2018, and data collection is ongoing. Linked data from all listed data sets are expected to be complete in September 2020.
CONCLUSIONS
The SAFEBOD study will overcome current limitations in organ donation by accessing comprehensive information on referred organ donors and recipients in existing data sets. The study will provide robust estimates of disease transmission and nontransmission events based on recent data. It will also describe the agreement between perceived risk estimated at the time of referral and verified risk when all health outcome data are accessible. The improved understanding of transmission and nontransmission events will inform clinical decisions and highlight where current policies can be revised to broaden the acceptance of deceased donors.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
DERR1-10.2196/18282.

Identifiants

pubmed: 33104005
pii: v9i10e18282
doi: 10.2196/18282
pmc: PMC7652689
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e18282

Investigateurs

Michael O’Leary (M)
William Rawlinson (W)
Geoff McGaughan (G)
Anne Keogh (A)
Stephen McDonald (S)
David Currow (D)
Jeremy Chapman (J)
Lee Taylor (L)
Rebecca Hancock (R)

Informations de copyright

©Brenda Rosales, James Hedley, Nicole De La Mata, Claire M Vajdic, Patrick Kelly, Kate Wyburn, Angela C Webster, The SAFEBOD Study Group. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 26.10.2020.

Références

Clin Transplant. 2010 Nov-Dec;24(6):735-46
pubmed: 20438579
Transplantation. 2015 Feb;99(2):282-7
pubmed: 25594557
Transplant Direct. 2019 Oct 17;5(11):e504
pubmed: 31773057
Am J Transplant. 2009 Aug;9(8):1929-35
pubmed: 19538493
Am J Transplant. 2013 Oct;13(10):2645-52
pubmed: 24034231

Auteurs

Brenda Rosales (B)

Sydney School of Public Health, The University of Sydney, Camperdown, Australia.

James Hedley (J)

Sydney School of Public Health, The University of Sydney, Camperdown, Australia.

Nicole De La Mata (N)

Sydney School of Public Health, The University of Sydney, Camperdown, Australia.

Claire M Vajdic (CM)

Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.

Patrick Kelly (P)

Sydney School of Public Health, The University of Sydney, Camperdown, Australia.

Kate Wyburn (K)

Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia.

Angela C Webster (AC)

Sydney School of Public Health, The University of Sydney, Camperdown, Australia.
Renal Medicine and Transplantation, Westmead Hospital, Westmead, Australia.
See Acknowledgments, .

Classifications MeSH